Plus Gilead, Adagio, White House and more To view this email as a web page,
click here Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after 'extremely rare' blood clot cases CDC study examines racial and ethnic disparities in COVID-19 hospitalizations Gerngross' Adagio starts testing antibody in COVID-19 patients Gilead nixes Veklury COVID-19 trial as vaccines roll out, more convenient drugs emerge for outpatients COVID-19 tracker: EU probes J&J for clarification over vaccine delay; Rigel touts oral drug data in hospitalized patients UPDATED Coronavirus tracker: White House says J&J vaccine pause won't affect rollout Resilience keeps expansion spree rolling with buyout of biologics maker Ology Featured Story | By Eric Sagonowsky After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials have called for an immediate pause to the rollout. read more |
| |
|---|
|
Top Stories By Robert King A new CDC study found racial and ethnic minorities had a higher proportion of COVID-19 hospitalizations than whites. read more By Nick Paul Taylor Tillman Gerngross’ Adagio Therapeutics has begun recruitment in a clinical trial of anti-SARS-CoV-2 antibody ADG20. The study is assessing the effect of a single dose of ADG20 on patients with mild to moderate COVID-19 and a high risk of disease progression. read more By Angus Liu Gilead Sciences has been exploring its antiviral remdesivir for COVID-19 in the outpatient setting, hoping to replicate the success seen in hospitalized patients. But as new treatments emerge, the company now thinks the drug, in its current form, simply doesn’t have a role to play outside hospitals. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky The European Commission is asking J&J for clarification surrounding its decision to halt vaccine deliveries to the EU. Several states and retail pharmacy chains are suspending J&J's shot following calls from federal health officials. Rigel finds fostamatinib may help treat hospitalized COVID-19 patients. And more headlines. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner National Resilience is wasting no time building out its biomanufacturing network, which it promised would be the “world’s most advanced" when it launched in November. After buying a pair of commercial facilities last month, Resilience has snapped up biologics drug substance specialist Ology Bioservices. read more |
|
